# Phase II, 2nd Line Melanoma - RAND Monotherapy

> **NCT00612664** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 158 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Anti-CD137 (4-1BB) (BMS-663513)

## Key facts

- **NCT ID:** NCT00612664
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612664, "Phase II, 2nd Line Melanoma - RAND Monotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00612664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*